CEO: Gal Cohen
Field: Burn & wound management
Lead product: NexoBrid™
Stage: Sales
CBI holdings: 45%

MediWound Ltd. (Nasdaq: MDWD) is a biotechnology niche specialty company. Established in 2001, MediWound is focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burn and chronic wound management.

MediWound’s goal is to provide healthcare professionals and patients with its innovative, burn wound eschar removal agent, NexoBrid™ and wound treatment technology PolyHeal™.
These two uniquely differentiated and innovative products have successfully completed clinical development and are approved in the European market as well as additional markets.

MediWound’s innovative medicinal product, NexoBrid™, is indicated in Europe for removal of eschar in adults with deep partial- and full-thickness thermal burns. MediWound acquired the commercial rights for PolyHeal™, innovative Negatively Charged Microspheres (NCM)-technology, CE-marked device indicated for the treatment of chronic and hard-to-heal wounds. PolyHeal™ is approved in Europe, Russia and Israel.

MediWound operates a cGMP and ISO13485 manufacturing facility for sterile pharmaceutical products and medical devices that meets high quality requirements.